Abstracts tagged "gout"

Abstract Number: 1131 • ACR Convergence 2025
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
Yuqi wang¹, Lingjiang Zhu¹, Jinshuo Han², Junbin Qian³, Martin Herrmann⁴, Jing Xue¹ and Lei Liu¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), ³Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 2008 • ACR Convergence 2025
Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Natalie McCormick¹, Sharan Rai², Chio Yokose³, leo lu⁴, Robert Terkeltaub⁵, Lama Nazzal⁶, Huilin Li⁶, Dylan Dodd⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Retired, San Diego, CA, ⁶NYU Langone, New York, NY, ⁷Stanford University, Palo Alto, CA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: As reported in Cell Press journals,1,2 intestinal commensal purine-degrading bacteria anaerobically degrade urate to anti-inflammatory short chain fatty acids, including butyrate, and thus may…
Abstract Number: 1923 • ACR Convergence 2025
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
John Botson¹, Menaka Bhor², Nathan Meyer², Molly Edwards³, Emily Goddard³, Victoria Barton⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians of Alaska, Anchorage, AK, ²Sobi Inc, Waltham, MA, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Western Washington Arthritis Clinic, Bothell, WA
Background/Purpose: Managing uncontrolled gout (UG) can involve a multi-disciplinary approach involving physicians of different specialities, all of whom may have differing perspectives or approaches for…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 2007 • ACR Convergence 2025
Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Min Jung Kim¹, Sang Min Lee², Jun Seok Kim², Borim Ryu² and Kichul Shin³, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ²Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government–Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea, ³Seoul National University, Seoul, South Korea
Background/Purpose: Long-term hyperuricemia is essential for the development of gout. However, only 9.9% of individuals with asymptomatic hyperuricemia (AHU) develop gout within 10 years. Identifying…
Abstract Number: 1907 • ACR Convergence 2025
Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021
Shiza sarfraz, Hassam Ali and debargha basuli, East Carolina University Brody School of Medicine, Greenville, NC
Background/Purpose: Gout is the most common inflammatory arthritis and an important driver of chronic disability. However, long-term trends in gout burden across U.S. states are…
Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Jose Doménech Serrano¹, Ivana García Loiseau², Cristina RodrÍguez-Alvear³, Pablo Riesgo Sanchis¹, Oscar Moreno Pérez¹ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Virgen de la Peña General Hospital, Fuerteventura, Spain
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…
Abstract Number: 2618 • ACR Convergence 2025
Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers
Abimbola Fadairo-Azinge¹, gabriela Schmajuk², Sristi Sharma³, Colleen Flanagan⁴, Sara Faghihi-Kashani⁵ and Mary Whooley⁶, ¹UNIVERSITY OF CALIFORNIA SAN-FRANCISCO, SAN FRANCISCO, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISCO, ⁴UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISO, ⁵UCSF, Mountain View, CA, ⁶SFVA, San Francisco
Background/Purpose: The American College of Rheumatology recommends HLA-B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and Black/African American patients, due to their…
Abstract Number: 2006 • ACR Convergence 2025
Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
Lesley Jackson¹, Rahima Begum², Gary Cutter², Hyon K. Choi³, Brett Faine⁴, Nora G. Singer⁵, Natalie McCormick⁶, hamid shokoohi⁷, Blair Parry⁷, Oliva Nelson⁷, James Booth¹, Zachary Armor¹, John Osborne¹, Kenneth Saag⁸ and Maria I. ("Maio") Danila⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴University of Iowa, Iowa City, IA, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Massachusetts General Hospital, Boston, ⁷Massachusetts General Hospital, Boston, MA, ⁸The University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Patients with gout are frequently treated in the emergency department (ED) for flares but may not receive consistent outpatient care. Approaches to mitigate this…
Abstract Number: 1903 • ACR Convergence 2025
Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
Nidaa Rasheed¹ and Candice Reyes², ¹UCSF Fresno, Fresno, CA, ²VACCHCS, Fresno, CA
Background/Purpose: Gout is a chronic, inflammatory arthritis driven by monosodium urate (MSU) crystal deposition and elevated serum uric acid (SUA) levels, increasing the risk for…
Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Inna Orlova¹, Iryna Shapoval², Nataliia Shkolina¹, Nataliia Kuzminova¹ and Mykola Stanislavchuk³, ¹National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine, ²National Pirogov Memorial Medical University, Vinnytsya (Ukraine), Vinnytsya, Ukraine, ³National Pirogov Memorial Medical University, Vinnytsia, Vinnytsia, Ukraine
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…
Abstract Number: 2590 • ACR Convergence 2025
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Sharan Rai¹, Natalie McCormick², Xochitl Morgan³, Matthew Nayor⁴, Robert Terkeltaub⁵, Dylan Dodd⁶, Lama Nazzal⁷, Huilin Li⁷, Gary Curhan⁸, Curtis Huttenhower³ and Hyon K. Choi⁹, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, ⁴Boston University, Boston, ⁵Retired, San Diego, CA, ⁶Stanford University, Palo Alto, CA, ⁷NYU Langone, New York, NY, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Approximately 21% of US adults have hyperuricemia, the causal precursor for gout. Human cells do not degrade urate (due to uricase gene inactivation). However,…
Abstract Number: 2004 • ACR Convergence 2025
Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
Kanon Jatuworapruk¹, Binit Vaidya², ANA MONICA ESTRELLA³, MA. HANNA MONICA SOLLANO³, Ronaldo De Vera⁴, Ida Ayu Ratih Wulansari Manuaba⁵, Rakhma Hellmi⁶, Panchalee Satpanich⁷, Nittayawadee Aeamsaard⁸, MAHABALESHWAR MAMADAPUR⁹, Mustafa Alhayali¹⁰, Chang-Nam Son¹¹, Syahrul Sazliyana Shaharir¹², Galymzhan Togizbayev¹³ and Jose Paulo Lorenzo³, ¹Thammasat University, Pathumthani, Thailand, ²National Center for Rheumatic Diseases, Kathmandu, Nepal, ³Makati Medical Center, Makati, Philippines, ⁴Tricity Medical Center in Pasig City, Pasig, Philippines, ⁵Bali International University, Bali, Indonesia, ⁶Kariadi Hospital Medical Center, Semarang, Indonesia, ⁷Faculty of Medicine Vajira Hospital, bangkok, Thailand, ⁸Saraburi Hospital, Saraburi, Thailand, ⁹JSS MEDICAL COLLEGE AND HOSPITAL, Mysore, Karnataka, India, ¹⁰Baghdad Teaching Hospital, Baghdad, Iraq, ¹¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ¹²Universiti Kebangsaan Malaysia, Selangor, Malaysia, ¹³Qazaq College of Rheumatology, Almaty, Kazakhstan
Background/Purpose: The burden of gout is rising in low-income and middle-income countries in the Asia-Pacific region. However, individuals with gout in this region remain underrepresented…
Abstract Number: 1891 • ACR Convergence 2025
Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
Eva Kalra¹, Drumadala Gajbhiye², Chandana Tummala³ and Hardik Dineshbhai Desai⁴, ¹Trident Medical Center, North Charleston, SC, ²Government medical college Akola Maharashtra India ⁴⁴⁴⁰⁰¹, Akola, India, ³Internal Medicine, Vydehi Institute Of Medical Sciences and Research Centre, Whitefield-⁵⁶⁰⁰⁶⁶, Bangalore, Karnataka, India, Banglore, India, ⁴Ahmedabad, Gujarat, India, ³⁸²³⁵⁰, Ahmedabad, India
Background/Purpose: Gout, a chronic inflammatory arthritis driven by hyperuricemia, has become an increasingly significant cause of disability in the United States. Despite therapeutic advances, its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].